Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

By Christos E. Kyriakopoulos, Yu‐Hui Chen, M. Carducci, Glenn Liu, D. Jarrard, N. Hahn, D. Shevrin, R. Dreicer, M. Hussain, M. Eisenberger and 8 more. Journal of Clinical Oncology, 2018

911 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/f09dd4d0f6e8786bc1f193b62ca26133ea6e7a1b

Citations in the corpus

• Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. (2019, neutral): “Surgical or medical procedure 13 (2) 10 (2)”